Stockscreener 앱 받기
71.42
3.00%
-2.21
시간 외 거래:
71.00
-0.42
-0.59%
전일 마감가:
$73.63
열려 있는:
$73.76
하루 거래량:
464.56K
Relative Volume:
0.80
시가총액:
$4.90B
수익:
-
순이익/손실:
$-224.29M
주가수익비율:
-18.31
EPS:
-3.9
순현금흐름:
$-185.06M
1주 성능:
+4.74%
1개월 성능:
+7.74%
6개월 성능:
-20.94%
1년 성능:
+8.08%
1일 변동 폭
$71.08
$74.16
1주일 범위
$63.55
$74.99
52주 변동 폭
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
명칭
Nuvalent Inc
전화
508-446-2272
주소
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
NUVL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
71.42 | 4.90B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-14 | 업그레이드 | UBS | Neutral → Buy |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-10-24 | 개시 | UBS | Neutral |
| 2024-08-29 | 개시 | Barclays | Overweight |
| 2024-04-17 | 개시 | Jefferies | Buy |
| 2024-04-01 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | 재개 | Guggenheim | Buy |
| 2024-02-23 | 개시 | Robert W. Baird | Outperform |
| 2023-09-27 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-24 | 개시 | Guggenheim | Buy |
| 2023-01-18 | 개시 | Wedbush | Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
모두보기
Nuvalent Inc 주식(NUVL)의 최신 뉴스
Nuvalent, Inc. (NASDAQ:NUVL) Shares Sold by Dimensional Fund Advisors LP - Defense World
A Bullish 2025 Outlook For Nuvalent Inc (NASDAQ: NUVL) Shares - Stocksregister
Decoding Nuvalent Inc (NUVL): A Strategic SWOT Insight - GuruFocus
Nuvalent (NUVL) Targets Key Milestones with Solid Financial Backing | NUVL Stock News - GuruFocus
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results - Stock Titan
Financial Health Check: Examining Nuvalent Inc (NUVL)’s Key Ratios - DWinneX
Nuvalent, Inc. (NASDAQ:NUVL) Stock Holdings Lowered by Envestnet Asset Management Inc. - Defense World
When the Price of (NUVL) Talks, People Listen - news.stocktradersdaily.com
Nuvalent Inc (NUVL) looking to reclaim success with recent performance - Sete News
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results - Seeking Alpha
Nuvalent reveals preclinical data on cancer drug zidesamtinib - Investing.com
Nuvalent Announces Publication in Molecular Cancer Therapeutics - GuruFocus
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - PR Newswire
Nuvalent reveals preclinical data on cancer drug zidesamtinib By Investing.com - Investing.com UK
Indo-Asian News Service - Indo-Asian News Service (IANS)
Nuvalent, Inc. (NASDAQ:NUVL) Position Boosted by Wells Fargo & Company MN - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Nuvalent, Inc. (NUVL): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting - ADVFN
Is Nuvalent, Inc. (NUVL) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey
Nuvalent describes new ROS and ALK tyrosine kinase receptor inhibitors - BioWorld MedTech
UBS gives a Buy recommendation for Nuvalent Inc (NUVL) - knoxdaily.com
JPMorgan Chase & Co. Acquires 47,818 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Trend Tracker for (NUVL) - news.stocktradersdaily.com
Nuvalent Board Member Resigns, Joins Advisory Board - TipRanks
Alliancebernstein L.P. Purchases 500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Commonwealth Equity Services LLC Raises Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Sei Investments Co. Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent: Cannot Make Sense Of The Valuation - Seeking Alpha
Nuvalent stock touches 52-week low at $61.75 amid market shifts By Investing.com - Investing.com South Africa
Nuvalent stock touches 52-week low at $61.75 amid market shifts - Investing.com Australia
Norges Bank Invests $24.95 Million in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
KLP Kapitalforvaltning AS Buys New Shares in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib - Onco'Zine
Commit To Purchase Nuvalent At $55, Earn 11.9% Annualized Using Options - Nasdaq
(NUVL) On The My Stocks Page - news.stocktradersdaily.com
Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? - Yahoo
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Quantisnow
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Stake Cut by Virtu Financial LLC - MarketBeat
Teacher Retirement System of Texas Boosts Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Nuvalent chief development officer sells shares worth $292,468 By Investing.com - Investing.com Philippines
10 Best Debt Free Mid Cap Stocks to Buy Now - Insider Monkey
Nuvalent chief development officer sells shares worth $292,468 - Investing.com India
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 - Nasdaq
Breakthrough Cancer Drug Data: New Brain-Penetrant Therapy Shows Promise Against Resistant Tumors - Stock Titan
Recent Insider Activity Suggests Potential Gains for Nuvalent Inc (NUVL) - knoxdaily.com
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Raymond James Financial Inc. Acquires Shares of 133,964 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent Inc (NUVL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):